Study of efficacy of spray dried lactobacillus reuteri for helicobacter pylori infection treatment
Keywords:
efficacy, spray dried lactobacillus reuteri, helicobacter pylori infectionAbstract
The present study was conducted to study the effectiveness of spray dried Lactobacillus reuteri in treatment of Helicobacter pylori infection at a tertiary healthcare institute. We evaluated the compliance and outcome of spray dried Lactobacillus reuteri in the treatment of patients with Helicobacter pylori. In our study, we included patients who were positive for Helicobacter pylori on Rapid Urease test. We assessed Rapid urease test findings on follow up visit among the study subjects and observed that 63.64% study subjects reported Helicobacter pylori negative after treatment with spray dried Lactobacillus reuteri. The study showed that majority of the study subjects were females (54.55%), whereas 45.45% subjects were males, M:F ratio in the current study was 1:1.2. and the mean age of the study subjects was 41.61 ± 10.84 years. 54.55% study subjects belonged to rural area, whereas 45.45% subjects belonged to urban area. Our study’s results are comparable and similar to the other studies which show that Lactobacillus reuteri (Probiotics) are useful in the Helicobacter pylori infection treatment.
Downloads
References
Marshall BJ, Warren JR (1983). "Unidentified curved bacilli on gastric epithelium in active chronic gastritis". The Lancet. 321 (8336): 1273–5. doi:10.1016/S0140-6736(83)92719-8. PMID 6134060.
Marshall BJ, Warren JR (June 1984). "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration". The Lancet. 323 (8390): 1311–5. doi:10.1016/S0140-6736(84)91816-6. PMID 6145023.
Sweet, Melissa (2 August 1997). "Smug as a bug". The Sydney Morning Herald. Retrieved 28 January 2007.
Hernandez C, Serrano C, Einisman H, Villagran A, Pena A, et al. (2014) Peptic ulcer disease in Helicobacter pylori-infected children: clinical findings and mucosal immune response. J Pediatr Gastroenterol Nutr 59: 773-778.
Sung JE, Kuipers H (2009) EL-SERAG, Systematic review: the global incidence and prevalence of peptic ulcer disease. Alimentary pharmacology & therapeutics 29: 938-946.
Kusters JG, van Vliet AH, Kuipers EJ (2006) Pathogenesis of Helicobacter pylori infection. Clinical microbiology reviews 19: 449-490
Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of helicobacter pylori infection. Helicobacter. 2014;19(Suppl 1):1–5.
Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–490.
Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM, Mégraud F. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. Panminerva Med. 2016;58(4):304–317.
World Health Organization. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans. Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: IARC. 1994;61:177–240.
Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology. 1997;113(6):1983–1991
Lu B, Li M. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol. 2014;20(19):5660–5665.
Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13(1):2–9.
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.
Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr. 2007;137(3 Suppl 2):812S–818S.
Ruggiero P. Use of probiotics in the fight against helicobacter pylori. World J Gastrointest Pathophysiol. 2014;5(4):384–391.
Zhu XY, Liu F. Probiotics as an adjuvant treatment in helicobacter pylori eradication therapy. J Dig Dis. 2017;18(4):195–202.
Patel A, Shah N, Prajapati JB. Clinical application of probiotics in the treatment of helicobacter pylori infection--a brief review. J Microbiol Immunol Infect. 2014;47(5):429–437.
Wang ZJ, Chen XF, Zhang ZX, Li YC, Deng J, Tu J, et al. Effects of anti-helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microb Pathogenesis. 2017;109:156–161.
. https://www.ncbi.nlm.nih.gov/pubmed/24178436 . 2014 Sep;9(6):649-54. doi: 10.1007/s11739-013-1013-z. Epub 2013 Nov 1.Lactobacillus reuteri in the treatment of Helicobacter pylori infection.Dore MP1, Cuccu M, Pes GM, Manca A, Graham DY. Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica, University of Sassari, Viale San Pietro 8, 07100, Sassari, Italy, mpdore@uniss.it.
Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. Exp Ther Med. 2016;12(1):3–17.
Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr. 2001;73(2 Suppl):444S–450S.
Cain AM, Karpa KD. Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med. 2011;17(1):72–79.
Dharmani P, De Simone C, Chadee K. The probiotic mixture VSL#3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factor. PLoS One. 2013;8(3):e58671.
Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by helicobacter pylori? Aliment Pharmacol Ther. 2006;23(8):1077–1086.
Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of helicobacter pylori to the glycolipid receptors by probiotic lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;32(2):105–110.
Dore MP, Goni E, Di Mario F. Is there a role for probiotics in Helicobacter pylori therapy? Gastroenterol Clin North Am. 2015;44:565–575
Holz C, Busjahn A, Mehling H, et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob Proteins. 2015;7(2):91-100.
Imase K, Tanaka A, Tokunaga K, Sugano H, Ishida H, Takahashi S. Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi. 2007 Jul;81(4):387-93.
Muresan IAP, Pop LL, Dumitrascu DL. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia. Med Pharm Rep. 2019;92(4):352-355.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
